Expert review of anti-infective therapyHumansHIV InfectionsMaleAdultFemale
A 96-week efficacy and safety of BIC/FTC/TAF in ART-naïve HIV-1 infected patients in China.
Shiyun Lv, Quanmin Li, Peishan Du, Xuemei Ling, Huolin Zhong, Huijun Hou, Jingliang Chen, Lijuan Chen, Yun Lan, Xiaoping Tang, Linghua Li
Published: 202510.1080/14787210.2025.2584555
Abstract
BACKGROUND: To evaluate 96-week virologic, immunologic, resistance and metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in antiretroviral therapy (ART)-naïve people living with HIV (PLWH). METHODS: Retrospe…
Preview only. Read the full abstract at the source